Table. Recommendations for non-live vaccine administration in people who are immunocompromised due to immunosuppressive therapies
Vaccine | Recommendation | Comments |
---|---|---|
COVID-19 |
|
Additional doses may be needed based on age, degree of immunocompromise and presence of other risk factors for severe illness from COVID-19. |
Diphtheria-tetanus-pertussis- and polio-containing vaccines a,b | Complete routine primary schedule or catch up for missed doses before starting the immunosuppressive therapies. | – |
Haemophilus influenzae type ba,b | Complete routine primary schedule or catch up for missed doses before starting the immunosuppressive therapies. | – |
Hepatitis B a,b | 1 booster dose for seronegative people with specific at risk conditions | – |
Human papillomavirus | Aged ≥9 years: a 3-dose primary schedule | Vaccination may also be considered in younger people who are immunocompromised if there is risk of exposure to HPV |
Influenza | 1 dose annually |
|
Japanese encephalitis (inactivated) | Use if indicated | See also Vaccination for international travellers. |
Meningococcal |
For people with acquired complement deficiency due to complement inhibitor:
|
The number of doses depends on the vaccine brand and the person’s age when they start the vaccine course. See Table. Recommendations for MenACWY vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease and Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease |
Mpox (live, non-replicating) | Use if indicated or seek specialist advice on individual risks and benefits of vaccination | – |
Pneumococcal(conjugate and polysaccharide vaccines) |
Routine age-appropriate primary course and following additional doses are recommended:
|
|
Rabies | Use if indicate | See also Travellers who are immunocompromised. |
Immunisation against respiratory syncytial virusa | Adults ≥60 years: 1 primary dose of RSV vaccine At-risk neonates and infants aged <24 months: 1 primary dose of RSV-specific monoclonal antibody | – |
Zoster (herpes zoster, recombinant) | Aged ≥18 years if immunocompromised: a 2-dose primary schedule | – |
Acronyms used:
Footnotes: a Recommended but not funded under the National Immunisation Program |
Related diseases
Related chapters
Page history
Last updated
Last reviewed